Navigation Links
Biomerix Corporation and Synthecon Announce Strategic Distribution Agreement
Date:9/20/2010

FREMONT, Calif., Sept. 20 /PRNewswire/ -- Biomerix Corporation, a medical technologies company developing and manufacturing innovative regenerative medicine biomaterials, and Synthecon, a leading biotechnology company specializing in the design and manufacturing of rotating cell culture systems, today announced a strategic distribution agreement for three-dimensional cell culture scaffolds developed using Biomerix Corporation's unique biomaterial technology.

The Biomerix 3D Scaffold is a medical grade biomaterial that embodies a novel microarchitecture, consisting of an interconnected three dimensional network of cells and pores designed to support tissue ingrowth and biointegration. Used in concert with Synthecon's bioreactors, the 3D Scaffold serves as an ideal technology to create an environment conducive to the growth of cells and tissues. Under the agreement, Biomerix will develop and manufacture the Biomerix 3D Scaffold, which Synthecon will market and sell nationwide for research applications. Specific terms of the agreement were not disclosed.

"Synthecon investigators have had excellent results using this material in its Rotary bioreactors to create 3-D cell cultures. Synthecon is currently utilizing the Biomerix 3-D Scaffold in an NIH-funded project to scale-up production of hematopoietic stem cells. The fact that Biomerix 3-D Scaffold is already approved for human use and is very compatible with the Rotary Cell Culture System gives us a high degree of confidence that the combination of these two technologies will lead to many exciting applications in the field of tissue engineering," commented Bill Anderson, CEO of Synthecon.

"Partnering with Synthecon allows us to be on the forefront of regenerative medicine and represents a significant growth opportunity for our Company," said Kenneth Hayes, President and Chief Executive Officer of Biomerix Corporation. "Synthecon is well respected as a leader in 3D cell culture systems and we look forward to a productive partnership," he concluded.

About Biomerix Corporation

Biomerix Corporation develops and manufactures novel materials for the medical, industrial, and consumer markets. The Company has successfully developed its first biomaterial platform, the Biomerix Biomaterial™, which is a non-resorbable, polycarbonate polyurethane-urea scaffold that has been shown to support fibrovascular tissue in-growth in a wide range of preclinical studies. The Biomerix Biomaterial has received U.S. FDA clearance for vascular, orthopedic, and soft tissue repair applications.

For more information please call 888.308.3620 or visit www.biomerix.com

About Synthecon Inc.

Synthecon designs and manufactures rotating bioreactors used in cell culture and tissue engineering applications. In addition to being recognized as a "Fast Tech Fifty" company, Synthecon was a previous recipient of the "R&D 100" award for its technology. Originally based on a license from NASA for the rotating wall bioreactor, Synthecon has gone on to design and patent numerous innovations to the basic technology. Marketed under the trademark Rotary Cell Culture System™, Synthecon bioreactors are recognized in several hundred peer-reviewed scientific publications to be a leader in growing three-dimensional human tissue analogs.

For more information please call 800-853-074 or visit www.synthecon.com


'/>"/>
SOURCE Biomerix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Communication Intelligence Corporation Reports Third Quarter 2008 Financial Results
2. Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2008 Results
3. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
4. delSECUR CORPORATION Announces Appointment of the Companys President & CEO
5. $29.4 million grant establishes CTSI at NYU in partnership with Health and Hospitals Corporation
6. delSECUR CORPORATION Announces Agreement to Purchase the Intellectual Property Assets of the Corporation
7. delSECUR CORPORATION Announces Agreement to Purchase the Intellectual Property Assets of the Corporation
8. M2SYS Biometric Software Solution Selected By GHG Corporation
9. Harris Corporation Adds Broadband Satellite Data Mode to JTRS-Approved Falcon III(R) AN/PRC-117G Multiband Manpack Radio
10. GenVault Corporation to Present at the 2009 BIOCOM Investor Conference
11. GenVault Corporation to Present at the 2009 BIOCOM Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... and SANDY, Utah , March ... operates the highest sample volume laboratory in ... and UNIConnect, leaders in clinical sequencing informatics and molecular ... of a project to establish the informatics infrastructure for ... NSO has been contracted by the Ontario Ministry ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
Breaking Biology Technology: